AGY.LSE Allergy Therapeutics
- Market cap
- GBX 91.8M
- P/E
- -
- P/B
- 52.16x
- ROE
- -1,875.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2025.
Is AGY.LSE undervalued?
Graham numberThe Graham number of Allergy Therapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allergy Therapeutics fundamental analysis
No fundamental analysis for Allergy Therapeutics yet.
Allergy Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venom…
Full company profileAllergy Therapeutics financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Dec 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allergy Therapeutics annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 48.5M | 64.1M | 68.3M | 73.7M | 78.2M | 84.3M | 72.8M | 59.6M | 55.2M | 55.0M | 145M |
| Gross Profit | 34.4M | 47.4M | 51.3M | 55.3M | 57.5M | 61.8M | 49.0M | 32.7M | 29.7M | 25.1M | 77.3M |
| Operating Income | -12.1M | -1.98M | -6.70M | -1.84M | 4.46M | 4.03M | -13.0M | -34.9M | -35.3M | -29.5M | -47.7M |
| EBITDA | -10.1M | 191K | -4.56M | 254K | 11.7M | 7.61M | -8.69M | -36.2M | -30.7M | -29.4M | -39.1M |
| Net Income | -13.1M | -2.48M | -7.53M | 3.47M | 7.06M | 2.89M | -13.8M | -43.1M | -40.2M | -40.1M | -79.7M |
| EPS | -0.02 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.02 | -0.06 | -0.01 | -0.01 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 56.7M | 57.2M | 51.0M | 68.5M | 86.2M | 88.1M | 72.9M | 66.8M | 64.8M | 67.5M | 71.0M |
| Total Liabilities | 26.4M | 27.2M | 28.0M | 30.9M | 42.4M | 39.6M | 35.2M | 64.7M | 61.1M | 95.7M | 66.8M |
| Shareholders' Equity | 30.3M | 30.0M | 23.0M | 37.6M | 43.8M | 48.5M | 37.8M | 2.07M | 3.71M | -28.2M | 4.25M |
| Cash & Short-term Investments | 23.4M | 22.1M | 15.5M | 27.4M | 37.0M | 40.3M | 20.5M | 14.8M | 12.9M | 12.8M | 10.1M |
| Total Debt | 3.37M | 3.33M | 3.06M | 2.44M | 12.2M | 11.2M | 10.5M | 36.0M | 31.0M | 60.1M | 26.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.8M | 178K | -3.80M | 5.60M | 12.3M | 8.52M | -14.1M | -30.9M | -32.1M | -28.7M | -46.8M |
| Capital Expenditure | 1.23M | 1.50M | 2.01M | 2.81M | 2.55M | 2.56M | 3.06M | 4.67M | 3.40M | 3.26M | 11.2M |
| Free Cash Flow | -13.1M | -1.32M | -5.81M | 2.79M | 9.73M | 5.95M | -17.2M | -35.6M | -35.5M | -32.0M | -58.1M |
| Ratios | |||||||||||
| ROE | -43.1% | -8.3% | -32.7% | 9.2% | 16.1% | 5.9% | -36.5% | -2,084.8% | -1,084.3% | - | -1,875.1% |
| ROA | -23.1% | -4.3% | -14.8% | 5.1% | 8.2% | 3.3% | -18.9% | -64.5% | -62.0% | -59.4% | -112.2% |
| Net Profit Margin | -26.9% | -3.9% | -11.0% | 4.7% | 9.0% | 3.4% | -18.9% | -72.3% | -72.9% | -72.9% | -54.9% |
| Debt to Equity | 0.11x | 0.11x | 0.13x | 0.06x | 0.28x | 0.23x | 0.28x | 17.42x | 8.35x | - | 6.30x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allergy Therapeutics dividends
Allergy Therapeutics has not paid dividends in the last 9 fiscal years.
Who owns Allergy Therapeutics
- Insiders 88.78%
- Institutions 0.01%
- Public & others 11.22%
- Shares outstanding 6.33B
- Free float 702M
Allergy Therapeutics company profile
- Company name
- Allergy Therapeutics
- Ticker
- AGY.LSE
- ISIN
- GB00B02LCQ05
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 584
- Fiscal year end
- June
- Address
- Dominion Way, Worthing, United Kingdom, BN14 8SA
- Phone
- 44 1903 844 700
- Website
- allergytherapeutics.com
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Allergy Therapeutics management
10- Mr. Manuel LlobetCEO & Executive Director · born 1965
- Dr. Shaun Antony FurlongCFO & Executive Director · born 1976
- Mr. Helge Weiner-TrapnessChief Strategy Officer & Executive Chairman · born 1963
- Dr. Murray SkinnerChief Scientific Officer
- Ms. Sue BakerHead of Human Resources
- Simon PiggottHead of Clinical Science
- Mr. Alan BullimoreHead of Communication & Market Development
- Mr. Russell PicketGroup Financial Controller
- Ms. Karley Charlotte Mouatt CheesmanCompany Secretary
- Mr. Matthew HeathPrincipal Scientist